Literature DB >> 1329643

Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine.

L D Lewis1, F M Hamzeh, P S Lietman.   

Abstract

Incubation of Molt-4 cells in 4 microM 2'3'-dideoxycytidine did not produce a significant change in the mitochondrial ultrastructure after 4 days; however, by 12 days, the mitochondrial ultrastructure was distorted, with condensed cristae or vacuolization, or both. Concentration-dependent decreases in both cell growth (mean 50% inhibitory concentration, 4.70 +/- 0.5 microM) and mitochondrial DNA content (mean 50% inhibitory concentration, 0.46 +/- 0.06 microM) occurred after incubation with 2'3'-dideoxycytidine for 4 days.

Mesh：

Substances：

Year:  1992        PMID： 1329643      PMCID： PMC192440          DOI： 10.1128/AAC.36.9.2061

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Peripheral neuropathy in mitochondrial disease.

Authors:  G Pezeshkpour; C Krarup; F Buchthal; S DiMauro; N Bresolin; J McBurney
Journal:  J Neurol Sci       Date:  1987-02       Impact factor: 3.181

2.  Studies on the inhibition of mitochondrial DNA replication by 3'-azido-3'-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication.

Authors:  M V Simpson; C D Chin; S A Keilbaugh; T S Lin; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1989-04-01       Impact factor: 5.858

3.  Chloramphenicol neurotoxicity.

Authors:  O Ramilo; B T Kinane; G H McCracken
Journal:  Pediatr Infect Dis J       Date:  1988-05       Impact factor: 2.129

4.  Chloramphenicol--induced peripheral neuropathy (a case report).

Authors:  B S Bomb; H K Bedi
Journal:  J Assoc Physicians India       Date:  1974-08

5.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.

Authors:  T C Merigan; G Skowron; S A Bozzette; D Richman; R Uttamchandani; M Fischl; R Schooley; M Hirsch; W Soo; C Pettinelli
Journal:  Ann Intern Med       Date:  1989-02-01       Impact factor: 25.391

7.  Chloramphenicol-induced mitochondrial and ultrastructural changes in hemopoietic cells.

Authors:  L F Skinnider; F N Ghadially
Journal:  Arch Pathol Lab Med       Date:  1976-11       Impact factor: 5.534

8.  Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

Authors:  R W Klecker; J M Collins; R C Yarchoan; R Thomas; N McAtee; S Broder; C E Myers
Journal:  J Clin Pharmacol       Date:  1988-09       Impact factor: 3.126

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Respiratory enzymes and mitochondrial morphology of HeLa and L cells treated with chloramphenicol and ethidium bromide.

Authors:  M E King; G C Godman; D W King
Journal:  J Cell Biol       Date:  1972-04       Impact factor: 10.539
View more
  9 in total

Review 1.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 2.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

3.  Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration.

Authors:  F C Richardson; J A Engelhardt; R R Bowsher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

4.  Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.

Authors:  Edward G Bridges; Jules R Selden; Shouqi Luo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

5.  Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides.

Authors:  D J Medina; C H Tsai; G D Hsiung; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

6.  The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain.

Authors:  Shuanglin Hao
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

Review 7.  Addressing the selectivity and toxicity of antiviral nucleosides.

Authors:  Joy Y Feng
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

8.  CD133 is a marker of bioenergetic stress in human glioma.

Authors:  Corinne E Griguer; Claudia R Oliva; Eric Gobin; Pascale Marcorelles; Dale J Benos; Jack R Lancaster; G Yancey Gillespie
Journal:  PLoS One       Date:  2008-11-05       Impact factor: 3.240

9.  Mitochondrial DNA depletion causes decreased ROS production and resistance to apoptosis.

Authors:  Hulin Chen; Junling Wang; Zhongrong Liu; Huilan Yang; Yingjie Zhu; Minling Zhao; Yan Liu; Miaomiao Yan
Journal:  Int J Mol Med       Date:  2016-08-03       Impact factor: 4.101
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.